Pulmonary Exam Questions With Complete Solutions
Which statement is FALSE?
A. Long acting, inhaled beta agonists should not to be used to
treat acute symptoms or exacerbations of asthma
B. Long acting, inhaled beta agonists are most effective at
treating asthma when used by themselves and not combined
with any other drug (e.g. corticosteroids)
C. Long acting, inhaled beta agonists have potential side effects
that include tachycardia, skeletal muscle tremor, hypokalemia,
prolongation of QT interval in overdose.
D. Long acting, inhaled beta agonists (if used by themselves)
may cause a diminished broncho-protective effect may occur
within 1 week of chronic therapy.
B
Which side effect(s) may occur with inhaled, long acting inhaled
beta agonists?
A. Tachycardia
B. Tremor
C. Hypokalemia
D. Diminished broncho-protective effect
E. All of the above are side effects with inhaled, long-acting
beta agonists
E
,Inhaled beta agonists work by:
A. Smooth muscle relaxation following adenylate cyclase
activation and increase in cyclic AMP producing functional
antagonism of bronchoconstriction.
B. May inhibit mast cell mediator release,
C. May decrease vascular permeability
D. May increase mucociliary clearance.
E. All of the above are mechanisms of action of the beta
agonists
E
Which drug is classified as a leukotriene receptor antagonist
(LTRA)?
A. Montelukast
B. Zileuton
C. Cromolyn
D. Budesonide
E. All of the above are leukotriene receptor antagonist (LTRA)
A
Which statement is TRUE?
A. Zafirlukast is extremely effective at preventing exacerbations
of COPD
B. Montelukast should only be used as an “acute relief
medication” in the treatment of asthma
, C. Leukotriene inhibitors may be effective for long-term control
and prevention of symptoms in mild or moderate persistent
asthma
D. Leukotriene inhibitors may be effective for long-term control
and prevention of symptoms of COPD
C
Which statement is TRUE?
A. Leukotriene inhibitors may be effective for long-term control
and prevention of symptoms of COPD
B. Montelukast will commonly induce a resistance to inhaled
beta agonists
C. Hypokalemia is a common adverse effect of leukotriene
inhibitors
D. Montelukast can be described as a “controller medication” in
the treatment of asthma
D
Which statement is TRUE?
A. Cromolyn is classified as a long-acting leukotriene inhibitor
B. Because of its effect on the beta-2 receptor, tolerance
develops quickly to cromolyn.
C. Cromolyn can stabilize mast cell membranes and inhibit
activation and release of mediators from eosinophils and
epithelial cells.
Which statement is FALSE?
A. Long acting, inhaled beta agonists should not to be used to
treat acute symptoms or exacerbations of asthma
B. Long acting, inhaled beta agonists are most effective at
treating asthma when used by themselves and not combined
with any other drug (e.g. corticosteroids)
C. Long acting, inhaled beta agonists have potential side effects
that include tachycardia, skeletal muscle tremor, hypokalemia,
prolongation of QT interval in overdose.
D. Long acting, inhaled beta agonists (if used by themselves)
may cause a diminished broncho-protective effect may occur
within 1 week of chronic therapy.
B
Which side effect(s) may occur with inhaled, long acting inhaled
beta agonists?
A. Tachycardia
B. Tremor
C. Hypokalemia
D. Diminished broncho-protective effect
E. All of the above are side effects with inhaled, long-acting
beta agonists
E
,Inhaled beta agonists work by:
A. Smooth muscle relaxation following adenylate cyclase
activation and increase in cyclic AMP producing functional
antagonism of bronchoconstriction.
B. May inhibit mast cell mediator release,
C. May decrease vascular permeability
D. May increase mucociliary clearance.
E. All of the above are mechanisms of action of the beta
agonists
E
Which drug is classified as a leukotriene receptor antagonist
(LTRA)?
A. Montelukast
B. Zileuton
C. Cromolyn
D. Budesonide
E. All of the above are leukotriene receptor antagonist (LTRA)
A
Which statement is TRUE?
A. Zafirlukast is extremely effective at preventing exacerbations
of COPD
B. Montelukast should only be used as an “acute relief
medication” in the treatment of asthma
, C. Leukotriene inhibitors may be effective for long-term control
and prevention of symptoms in mild or moderate persistent
asthma
D. Leukotriene inhibitors may be effective for long-term control
and prevention of symptoms of COPD
C
Which statement is TRUE?
A. Leukotriene inhibitors may be effective for long-term control
and prevention of symptoms of COPD
B. Montelukast will commonly induce a resistance to inhaled
beta agonists
C. Hypokalemia is a common adverse effect of leukotriene
inhibitors
D. Montelukast can be described as a “controller medication” in
the treatment of asthma
D
Which statement is TRUE?
A. Cromolyn is classified as a long-acting leukotriene inhibitor
B. Because of its effect on the beta-2 receptor, tolerance
develops quickly to cromolyn.
C. Cromolyn can stabilize mast cell membranes and inhibit
activation and release of mediators from eosinophils and
epithelial cells.
